Venclexta
venetoclax
APPROVED
Drug Profile
ModalitySmall molecule
RoutePO
Therapy AreaOncology
Launch2016-04-11
US LOE2032-01-01
Peak Sales Est$4000M
Formulations[{"id":"venclexta-po","doses":"10-400mg","route":"PO","setting":"OUTPATIENT","frequency":"Once daily
Mechanism: BCL-2 inhibitor
Expert: Small molecule BH3 mimetic that selectively binds BCL-2, releasing pro-apoptotic proteins and inducing apoptosis in CLL/AML cells.
Everyday: Blocks a protein that helps cancer cells survive, causing them to die.
Targets: ["BCL-2"]
Revenue History
| Period | Revenue ($M) |
|---|
| 2024 | $2,590M |
| 2025 | $2,792M |
| Q4 2025 | $735M |
Programs (4)
| Indication | Stage | Key Study | Regional Status |
|---|
| HR-MDS | PHASE3 | VERVE-MDS | [] |
| 1L CLL | APPROVED | CLL14 | [{"stage":"APPROVED","region":"US","approval_date":"2019-05-15"},{"stage":"APPRO |
| R/R CLL | APPROVED | MURANO | [{"stage":"APPROVED","region":"US","approval_date":"2016-04-11"},{"stage":"APPRO |
| R/R AML | APPROVED | VIALE-A | [{"stage":"APPROVED","region":"US","approval_date":"2018-11-21"},{"stage":"APPRO |
Upcoming Catalysts (1)
Venclexta - HR-MDS - FDA Approval
2026
Notes
First-in-class BCL-2 inhibitor for CLL and AML. Co-developed with Roche/Genentech. 2025 revenue $2.8B (+8% YoY). Expanding into higher-risk MDS (Phase 3).
Data from Supabase · Updated 2026-03-24